Review of the fibrinolytic system: comparison of different antifibrinolytics used during cardiopulmonary bypass

Van Aelbrouck, Caroline; Englberger, Lars; Faraoni, David (2012). Review of the fibrinolytic system: comparison of different antifibrinolytics used during cardiopulmonary bypass. Recent patents on cardiovascular drug discovery, 7(3), pp. 175-9. Sharjah: Bentham Science

Full text not available from this repository. (Request a copy)

Antifibrinolytic agents are often used in different clinical situations, especially in cardiac surgery. During several years, aprotinin was the drug of choice because more than antifibrinolytic properties, aprotinin offers a direct effect on kallikrein and inflammatory pathways. In 2008, The Blood Conservation Using Antifibrinolytics in a Randomized Trial (BART) initiated a discussion about real risks associated with aprotinin administration. Tranexamic acid and epsilon-aminocaproic acid appear to be interesting alternatives in our daily practice. The exact mechanism of action, the pharmacokinetic parameters, the efficacy, and the safety profile need to be clarified for lysine analogs. In this review, the different antifibrinolytics will be described with a special interest into the route of work, and recent patents. Current studies about the pharmacokinetic and the pharmacodynamic profile will be described, and finally the benefit-to-risk balance in patients undergoing cardiac surgery with cardiopulmonary bypass will be discussed.

Item Type:

Journal Article (Further Contribution)

Division/Institute:

04 Faculty of Medicine > Department of Cardiovascular Disorders (DHGE) > Clinic of Cardiovascular Surgery

UniBE Contributor:

Englberger, Lars

ISSN:

1574-8901

Publisher:

Bentham Science

Language:

English

Submitter:

Factscience Import

Date Deposited:

04 Oct 2013 14:37

Last Modified:

17 Mar 2015 21:27

PubMed ID:

23035827

URI:

https://boris.unibe.ch/id/eprint/14751 (FactScience: 221862)

Actions (login required)

Edit item Edit item
Provide Feedback